SOUTH AFRICA IS A MIDDLE-INCOME country with a severe HIV epidemic. 1, 2 Since 1990, the national HIV prevalence has risen from 0.7% to 25% 3 among antenatal attendees and reached 11.4% in the general population by 2002. 4 Young women are the worst affected, with antenatal attendees aged 25 to 29 having a prevalence of 31.4%, 1 and an incidence of up to 25 infections per 100 person-years. 5 A recent survey estimated that approximately 8.4 million sexually transmitted infections (STIs) occurred in South Africa in 2002 among a population of (15 years or older) approximately 30 million. 6 This is despite numerous HIV and STI preventive campaigns centered largely on behavioral change. 7 A number of HIV prevention interventions in South Africa have been evaluated. 9 -14 These studies show that it is possible to achieve significant increases in condom use and improvements in STI treatment. Importantly, in one mining community in South Africa, an STI treatment intervention providing periodic presumptive treatment for bacterial STIs (PPT) to high-risk women was shown to be effective in reducing the prevalence of STIs, 14 but the cost-effectiveness was not estimated. To date, one study has estimated the impact of this type of intervention on HIV transmission and was unable to demonstrate any impact. 15 It has been argued that targeted interventions are especially cost-effective in early concentrated epidemics, 8 but a key policy question is whether they are still cost-effective in generalized epidemics, like in South Africa. This study uses economic analysis and mathematical modeling to estimate the cost-effectiveness of a hotel-based STI intervention for female sex workers (FSWs) in Hillbrow, Johannesburg (July 2000 -June 2001). The intervention used syndromic management and PPT to treat women attending the on-site clinic.
Materials and Methods

Study Site
Hillbrow and adjacent suburbs are part of inner-city Johannesburg. The population is highly mobile, and sex work is common with an estimated 3000 to 5000 FSWs 16 within an adult population of approximately 100,000. 17 Sex work in Hillbrow is both hoteland street-based. The prevalence of HIV and other STIs is high, with 45% to 54% of FSWs and 22% of female family planning clients (FPs) infected with HIV and 39% of FSWs and 24% of FP clients infected with Chlamydia trachomatis (CT) or Neisseria gonorrhoeae (GC) in 1998. 16, 18 Although there are 5 primary health clinics (PHCs) in Hillbrow, long waiting times and perceived judgmental attitudes of clinic staff discourage FSWs from attending them. 19 Many women prefer private practitioners, who are faster and confidential but provide poor-quality treatment. 20 Within this context, and the high STI/HIV prevalence, it is crucial that quality STI services are provided to such a vulnerable population. 21 In June 2000, the Reproductive Health Research Unit (RHRU), with the local authority, initiated an STI intervention in Hillbrow to provide STI treatment to FSWs working in hotels and to strengthen STI services in PHCs.
The Female Sex Worker Sexually Transmitted Infection Intervention
The FSW intervention used a mobile clinic to provide monthly STI services in 12 of the 25 hotels where women practice sex work. Services included syndromic management of symptomatic STIs, health education, safe-sex negotiation skills, and condom distribution. In addition, the women in 6 of the hotels received PPT with azithromycin (1 g), whereas the others received a vitamin pill. All women were asked to return to the clinic monthly.
The STI clinic came to each hotel for approximately 3 days per month and was operated by a nurse and a community health worker (CHW). FSWs in the hotel were encouraged to attend the clinic irrespective of whether they had STI symptoms or not. The CHW provided women with condoms, information about STIs, and how to negotiate safer sex. The FSWs were then seen by a nurse who treated their STI syndromes according to provincial guidelines 22 and gave them PPT or vitamins.
Between July 2000 and June 2001, 1431 FSWs attended the STI clinic. There were 2523 visits and 1086 STI syndromes treated. On average, 18% of the targeted FSWs were contacted per month (Ͻ5% of the Hillbrow FSWs) and were given 19 condoms per visit on average. Only 57% of the women came for more than one visit, with on average 4.5 months between visits. In the 6 PPT hotels, 1193 azithromycin doses were distributed to 960 FSWs.
Costing
Cost collection followed the methods outlined in the UNAIDS Costing Guidelines for HIV Prevention Strategies. 23 Costs were collected retrospectively from a provider's perspective using an ingredients-based methodology. Annual financial and economic costs were estimated for the project's first year (July 2000 -June 2001). Financial costs represent actual expenditure. Economic costs represent the estimated market value of all resources used, including donated goods and services. Annual financial capital costs were calculated using straight-line depreciation, the total cost of the goods being divided by its estimated working life. Economic capital costs were annualized using a 3% discount rate to obtain the opportunity cost of using the resources elsewhere. Cost data were collated using project accounts from RHRU, records of drugs and supplies used by the clinic, district records of condom donations, discussions with project staff, and observation at the intervention clinic. Full costs for the startup and implementation of the intervention were included. Costs for research-related activities were excluded.
The average exchange rate in the year of expenditure was used to convert costs into U.S. dollars (US$), 7.61 Rand per US$. All costs presented in this article, including costs from other studies, have been adjusted to 2001 US$. The cost analysis relied on a number of assumptions such as the amount of time spent on research and the implementation of the intervention. The impact of these assumptions is explored in the sensitivity analysis.
Model Description
A deterministic, compartmental model (POP 1.0) was developed to estimate the impact of the intervention on HIV transmission among the FSWs and the general population in Hillbrow. The model divides the population into subgroups according to their levels of sexual behavior, condom use ("none of the time," "half of the time," and "all of the time"), and HIV and STI status. Four categories of sexual behavior are defined for individuals with: no sexual partners, just long-term sexual partners, long-term partners and casual partners, and those who are FSWs or clients of FSWs. In the model, individuals in these subgroups form sexual partnerships with defined durations, coital frequencies, and levels of condom use. The model uses established mathematical techniques to estimate how HIV and CT/GC spread within the subgroups over time. 24 Because of the absence of prevalence data, specific ulcerative STIs are not modeled. However, because of the importance of symptomatic ulcerative STIs in facilitating HIV transmission, and the availability of genital ulcer disease (GUD) prevalence data, symptomatic ulcerative STIs were modeled as a whole to incorporate their influence on HIV transmission into the analysis. The probability that an individual becomes infected with HIV, GC/CT, or an ulcerative STI from one of their sexual partners depends on their coital frequency, level of condom use, and the probability that the partner is infected. Once an individual is infected with GC/CT, they remain infectious for a fixed duration or until treated, whereupon they become susceptible again. Once an individual has a symptomatic ulcerative STI, their ulcers remain for a fixed duration or until treated (except for those resulting from herpes simplex virus type 2 ). In the model, HIV-infected individuals remain infectious for 84 months, and then they are assumed to leave the sexually active population as a result of chronic AIDS morbidity or death. The model structure is shown in Appendix 1.
The model simulates the patterns of HIV infection in the population in the presence and absence of the intervention. 25 Comparisons between the 2 are used to estimate infections averted among the FSWs and the general population. Importantly, the model incorporates how GC/CT or symptomatic ulcerative STIs facilitate HIV transmission 26 and how the intervention affects HIV transmission through STI treatment. Among the FSWs who attended the STI clinic in the PPT hotels, PPT was assumed to effectively treat all GC/CT infections and a proportion of the GUD cases that were not identified and treated using syndromic management. The model also incorporates the higher infectivity associated with primary HIV. 27 
Epidemiologic Data
Data on STI prevalences among FSWs were collected from clinic records of all the FSWs attending the intervention from July to September 2000 (n ϭ 310) and June to September 2001 (follow-up visits, n ϭ 550) and an epidemiologic survey (n ϭ 226) undertaken by a FSW outreach program in Johannesburg in 1998. 18 Estimates of the prevalence of GC, CT, Treponema palladium (syphilis), and GUD for sexually active females were obtained from an epidemiologic survey of 210 consecutive women attending a FP clinic in Johannesburg in 1998 18 and the National HIV and Syphilis Sero-prevalence Survey of women attending public antenatal clinics in South Africa. 1 The ligase chain reaction was used to detect for GC and CT in urine samples and the rapid plasma reagin (RPR) test was used to detect for T. palladium in blood samples. The only available STI prevalence data for sexually active males was from STI clinic clients in Johannesburg (n ϭ 741). 30 The data are presented in Table 1 Other inputs such as the duration between HIV infection and severe morbidity, [31] [32] [33] HIV and STI transmission probabilities, 34 -42 and STI cofactors 26 were obtained from the scientific literature. The adult mortality rate was obtained from 2001 demographic data for South Africa. 43 The model inputs are shown in Appendix 2.
Data Used to Parameterize Model
Model Uncertainty Analysis
Before using the model to estimate the impact of the intervention, it was fitted to epidemiologic data from Hillbrow. Uncertainty bounds were estimated around model input parameters using behavioral, epidemiologic, demographic, and intervention-specific data from the project site or the scientific literature (Appendix 2). Random sampling 44 was used to obtain 500 parameter sets from the uncertainty ranges (excluding intervention specific parameters). The model was run for each parameter set to simulate the epidemic that would occur. Any simulation that lay within the confidence intervals of the HIV, GC/CT, and GUD prevalence among FSWs attending the intervention in 2000, the HIV prevalence among antenatal clinic clients in 2000, and the prevalence of GC/CT among FP clients in 1998 was selected. The 1998 FP client data on GC/CT was used because there were no GC/CT prevalence data from 2000, except among FSWs. GUD prevalence data were used as a proxy for the prevalence of symptomatic ulcerative STIs.
Intervention Impact
Model simulations fitting the baseline epidemiologic data were used to estimate intervention impact. This entailed fitting the selected model simulations to intervention output and epidemiologic data from 2001 (Table 1 and Fig. 1 ) by varying interventionspecific model parameters within their uncertainty bounds. These parameters included the model inputs related to the intervention. 
ARE TARGETED HIV PREVENTION ACTIVITIES COST-EFFECTIVE?
Intervention output data used to fit the model included the number of clinic visits (2523), the number of syndromes treated (1094), and the number of PPT doses distributed (1193) in the intervention's first year. The simulation that most closely agreed with the baseline and postintervention data were used to produce point impact estimates. The other simulations were used to produce a range around this estimate.
The model simulations were used to estimate the 1-year impact of the intervention on the transmission of HIV, GC/CT, and ulcerative STIs, including the decrease in HIV incidence and prevalence of HIV, GC/CT, and ulcerative STIs and the infections averted among FSWs and the general population. The model's projections of the number of GC/CT infections and ulcerative STIs averted were used to estimate the number of GC, CT, chancroid, and syphilis infections averted by using data on the proportion of GC/CT infections and GUD syndromes resulting from laboratorydiagnosed GC, CT, HSV-2, chancroid, and syphilis. Instances of GUD caused by HSV-2 (27%) were assumed untreatable.
A univariate sensitivity analysis was undertaken using the "bestfit" model simulation to estimate how the impact projections were affected by a 10% deviation in specific model inputs.
Cost-Effectiveness
Cost-effectiveness ratios for the intervention were estimated using the economic costs and the modeled projections of HIV infections and disability-adjusted life years (DALYs) averted.
DALYs combine length of life with quality of life into a single measurement and enables multiple health benefits to be aggregated so the cost-effectiveness of different health interventions can be compared. The projections of the number of CT, GC, syphilis, and HIV infections averted were used to estimate the number of DALYs averted. DALYs were calculated using the methodology of Fox-Rushby and Hanson 45 and represent the sum of years of life lost as a result of premature mortality and years lived with disability adjusted for severity. 46 For this, the age of onset of disability was taken as the average age of the Hillbrow population. Age of death was the age of onset of disease plus the average time between acquiring infection and dying as given in the global burden of disease (GBD). 46 Duration of disability and the disability weight was taken from the GBD. 46, 47 The point estimate of the cost-effectiveness uses the best-fit model simulation and the central cost estimate. The low-end (best) cost-effectiveness ratio uses the lowest cost from the sensitivity analysis and the highest impact prediction, whereas the high-end estimate uses the highest costs and lowest impact prediction.
Relationship Among HIV Prevalence, Coverage, and Cost-Effectiveness
The best-fit model simulation was used to estimate the impact and cost-effectiveness of the intervention if it had been initiated at an earlier stage of the HIV epidemic in Hillbrow. This was done by obtaining impact estimates for lower initial HIV prevalences and assuming that there was no associated change in STI prevalences or costs. The model was also used to project the additional impact of either increasing the coverage of the intervention to reach all FSWs or mass-treating the FSWs, clients, and/or general population with PPT.
Results
Intervention Costs
Financial and economic costs of the project are presented in Table 2 . Economic costs of the intervention in its first year were $110,301. Capital costs made up 14% of total costs, primarily as a result of startup costs (9%). Personnel was the largest cost category (Ͼ50% of total costs). Because the district donated most STI drugs, condoms, and office space, there are large differences between the financial and economic costs of buildings and supplies. Conversely, without both STI treatment components, the model projects the intervention would have averted 12 (range, 10 -14) HIV infections resulting from the small increase in reported condom use by the FSWs with their clients. This is less than 50% of the estimated impact of either STI treatment component of the intervention by itself and only 22% of the estimated impact of the full intervention. Interestingly, the cumulative impact of the STI treatment components and condom aspect of the intervention is approximately additive.
For the current intervention, the economic cost per HIV infection averted was $2093 (range, $1384 -3635), or $78 (range, $53-121) per DALY averted. If FSWs had only been treated using syndromic management, then the cost per DALY averted increases to $85. The incremental cost of adding PPT to the intervention was only $31 per DALY averted.
Sensitivity Analysis
Key uncertainties in estimating the economic costs were staff time during startup. If the startup period took 2 days of the coordinators time per week, instead of one, the costs would be 3% higher. This not only reflects the increase in salary, but also the associated increase in overhead costs. If drug costs increased or decreased by 20%, total costs of the intervention would vary by 1%. The cost-effectiveness projections incorporate the maximum and minimum estimates of the costs obtained from this univariate sensitivity analysis.
A univariate sensitivity analysis was undertaken using the bestfit model simulation to estimate the sensitivity of the 1-year impact projections to a 10% deviation in specific parameters. The parameter that resulted in the greatest change in the HIV infections 11 (8) (9) (10) (11) (12) (13) (14) 9 (7-12) 13 (10-17) 11 (9) (10) (11) (12) (13) (14) 16 (13) (14) (15) (16) (17) (18) (19) (20) General population 9 (9-11)
23 (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) 18 (14-24) 32 (24-38) 28 ( 
ARE TARGETED HIV PREVENTION ACTIVITIES COST-EFFECTIVE?
averted was the proportion of women who are FSWs, a 10% increase resulted in an 11% increase in the HIV infections averted and a 10% decrease resulted in a 13% decrease. A 10% deviation in STI transmission probabilities and cofactors, and HIV transmission probabilities, resulted in deviations in the HIV infections averted of 5% to 10%. The impact predictions were fairly insensitive to deviations in other model parameters.
Relationship Between HIV Prevalence, Coverage, and Cost-Effectiveness
Had the intervention been initiated when the general HIV prevalence was 15%, 81 HIV infections would have been averted (54% increase) and the cost per HIV infection averted would have been $1355 (Fig. 2) . In contrast, if the intervention had been initiated when the general HIV prevalence was 1%, the cost-effectiveness would have been 143% higher. However, this is a short-term effect because the intervention impact increases rapidly as time progresses with 4 times the impact after 2 years. In addition, the intervention would have resulted in a greater relative decrease in HIV incidence if it had been initiated earlier in the epidemic (Fig. 2) .
During the intervention period, project staff estimated there to be approximately 850 FSWs residing in the 12 intervention hotels. This implies that between 17% and 28% of the 3000 to 5000 FSWs residing in Hillbrow were "reached" by the intervention, i.e., had easy access to one of the intervention clinics. If the same intervention was scaled up to "reach" all the FSWs in Hillbrow (instead of 17-28%), with both PPT and syndromic management, the impact of the intervention would have increased 3-fold, decreasing the HIV incidence among the general population and FSWs by 5% and 9%, respectively. In contrast, if they had adapted the intervention to actively contact and mass-treat all FSWs with PPT (with the same frequency as the existing intervention), the HIV incidence among the FSWs and general population would have decreased by up to 24% and 14%, respectively. If they had also attempted to mass-treat all the clients with PPT, the HIV incidence among the FSWs and the general population would have decreased by up to 40% and 28%, respectively. Lastly, if they had also mass-treated the general population, then the general population HIV incidence would have decreased by up to 47%.
Discussion
Targeted interventions are thought to be especially cost-effective in early concentrated epidemics, 8 but there is little evidence of their cost-effectiveness in generalized epidemics. This study shows that the cost-effectiveness of this intervention, providing STI treatment to FSWs in a high prevalence setting, falls below the suggested upper bound ($141 per DALY averted in U.S. $2001) of cost-effective interventions given by the World Development Report (WDR). 48 The intervention resulted in 53 HIV infections averted and 1413 DALYs averted, four fifths of which were the result of the STI treatment components of the intervention. The cost-effectiveness ratio of the intervention was $78 per DALY averted. This cost-effectiveness ratio is less than other accepted HIV interventions in South Africa such as the prevention of mother-to-child transmission ($225 per DALY averted) and antiretroviral therapy ($1800 per DALY averted). 49 -51 The analysis also shows that the cost-effectiveness of the intervention could have been improved by over 30% if it had been initiated at an earlier stage of the HIV epidemic. This supports the importance of targeted STI interventions in less generalized epidemics and the value of early intervention.
Importantly, the analysis showed how PPT can improve the cost-effectiveness of STI interventions in high-risk populations. The addition of PPT to 67% of the reached FSWs resulted in 15% more HIV infections averted for only 5% more costs, $31 per additional DALY averted. Indeed, if syndromic management had been removed from the intervention, the PPT component would have averted 73% of the HIV infections, although it was only available to 67% of the reached FSWs. This is the result of the low sensitivity of the syndromic approach for STI treatment.
The model projections are dependent on the reliability of available epidemiologic data, reported behavioral data, and HIV/STI transmission data. There is uncertainty in the estimates of the STI cofactors and STI/HIV transmission probabilities. There is little data on the prevalence of ulcerative STIs, especially HSV-2 and chancroid, except from GUD cases. This meant that specific ulcerative STIs could not be included in the model but were modeled simply as a whole. The CT/GC prevalence estimates for the FSWs and general population came from either the intervention, other districts of Johannesburg, or Gauteng or from 2 years before the intervention. 18 The uncertainty analysis was used to reflect this data uncertainty and resulted in considerable variability in the baseline projections. This variability was counteracted by only using the model simulations that fit available HIV and STI prevalence data from 2000.
In addition, uncertainty in STI-specific parameters such as the STI cofactors made it difficult to estimate the impact on HIV transmission of treating STIs. This uncertainty was incorporated into the uncertainty analysis and, therefore, in the impact estimates. The uncertainty does not affect the robustness of the conclusions because the upper-bound cost-effectiveness ratio is less than the WDR-suggested upper bound for cost-effective interventions.
Although effective in averting HIV and STIs, with over 5 STIs being averted for every STI treated among the FSWs, the model predicts that the intervention is unlikely to reduce the HIV prevalence among the general population in Hillbrow. Indeed, the drop in HIV incidence (3% among FSWs) is much lower than was recorded by the STI intervention in Mwanza. 52 Some possible explanations for this are the low coverage and uptake of the intervention, FSWs were highly mobile resulting in high loss to follow up, and the intervention did not treat the clients/partners of FSWs, resulting in frequent reinfection. If the intervention had been scaled up to "reach" all FSWs (i.e., all FSWs have easy access to an intervention clinic), the impact would have increased up to 3-fold, whereas if the intervention had contacted and masstreated all FSWs with PPT, the impact would have increased up to 9-fold. This illustrates the worth of actively contacting and treating all FSWs because many FSWs will not attend an intervention clinic because they feel they are at low risk. If they had also mass-treated their clients with PPT, the impact would have increased up to 14-fold. This highlights the importance of treating clients, as well as FSWs, when undertaking targeted STI treatment interventions. Lastly, mass treating the general population with PPT increases impact further, resulting in an upper-bound 47% decrease in HIV incidence among the general population, comparable to the Mwanza STI intervention.
These results highlight the importance of PPT as a strategy for rapidly reducing the prevalence of curable STIs in high STI prevalence settings. Once achieved, syndromic management should be sufficient as a treatment strategy. It is possible that the cost-effectiveness could have been improved by the sole use of PPT to initially mass-treat FSWs. In addition, PPT could be distributed to FSWs as a possible strategy for mass-treating their partners/clients. However, the feasibility of such distribution strategies needs to be explored.
The findings differ from the results of a recent study by Kaul et al. 15 that did not observe any decrease in HIV transmission when they treated FSWs with PPT in Kenya. However, this study was powered to detect a 50% decrease in HIV incidence among their FSW population, which may be overoptimistic, because for this specific setting, a 24% reduction in incidence would have occurred if all FSWs in Hillbrow had received PPT.
This study illustrates that targeted STI interventions using syndromic management and/or PPT can be cost-effective when the HIV epidemic is generalized and there is a high prevalence of STIs. However, for an STI intervention to have a significant impact on HIV transmission, they not only need to attain high coverage, but also treat the sexual partners of FSWs and improve STI treatment in the general population. In a setting such as Hillbrow, where high-risk behavior and STIs are prevalent, this may be supported by the more widespread provision of PPT. 
The population of "n" individuals is divided into those that are susceptible to HIV infection (x), those that are recently HIV-infected and in the initial high-viremia phase (h), and those that have progressed into the low-viremia phase (y). The subscripts r and j denote the sex and sexual activity (including level of condom use) of the individuals, respectively. New individuals enter the susceptible population at a fixed per-capita recruitment rate (⌳ r ). Susceptible individuals become infected with HIV at a per-capita rate that is determined by the risk associated with their sexual behavior ( sex ). When a susceptible individual becomes infected with HIV, they are initially highly infectious (average duration 1/). They then enter a long period of low infectivity (average duration 1/␦). In the model, individuals remain in the population until they move away (rate r ) or until they stop having sex as a result of chronic HIV-related illness. 
ͪ
The parameter x s denotes the number of individuals susceptible to STI infection and y s the number infected with an STI. Susceptible individuals become infected with an STI at a per-capita rate that is determined by the risk associated with their sexual behavior with other individuals ( s ). When a susceptible individual becomes infected with an STI, they remain infectious for a fixed period of time (1/ r ) and then become susceptible or noninfectious once more.
Probability that a susceptible individual becomes HIV-infected from an infected sexual partner per unit time
The probability that a susceptible individual becomes HIV-infected in "m" sex acts with an HIV-infected partner is one minus the probability that they remain uninfected in all "m" sexual acts they have with the infected individual. If condoms are used with consistency "f", then there is a probability "e" that the susceptible individual will be protected from infection and a probability ͓1 Ϫ ␤ sex (1 Ϫ ef)͔ that the individual was not HIV-infected in one sex act, where ␤ sex is the probability of HIV transmission per sexual act. The probability that the individual remains uninfected in "n" acts is ͓1 Ϫ ␤ sex (1 Ϫ ef)͔ n . The equation can be further extended to incorporate the role of high viremia or STIs. An analogous equation is used to describe the probability that a susceptible individual becomes infected with an STI. 
